Mediators of Inflammation / 2016 / Article / Tab 1

Review Article

Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials

Table 1

Celecoxib randomized clinical add-on trials.

AuthorsStudy designParticipantsTreatment durationCelecoxib dosesAntipsychoticsMajor findings

Müller et al. 2002 [108]Double-blind, randomized, placebo-controlled, add-on
Schizophrenics Duration of illness not specified (mean 5.9 years)
5 weeks400 mg/dayRisperidone
(flexible dose)
Significant advantage of the COX-2 inhibitor

Rappart and Müller 2004 [109]Double-blind, randomized, placebo-controlled, add-on
Schizophrenics Duration of illness ≤10 years
11 weeks400 mg/dayRisperidone
(flexible dose)
No advantage on the COX-2 inhibitor

Rapaport et al. 2005 [110]Double-blind, randomized, placebo-controlled, add-on
Schizophrenics Continuously ill (mean 20 years)
8 weeks400 mg/dayRisperidone or olanzapine
(constant dose)
No advantage on the COX-2 inhibitor

Zhang et al. 2006 [111]Double-blind, randomized, placebo-controlled, add-on
First manifestation schizophrenia
12 weeks400 mg/dayRisperidone
(flexible dose)
Significant advantage of the COX-2 inhibitor

Akhondzadeh et al. 2007 [112]Double-blind, randomized, placebo-controlled, add-on
Active phase of chronic schizophrenia
8 weeks400 mg/dayRisperidone
(flexible dose)
Significant advantage of the COX-2 inhibitor

Müller et al. 2010 [113]Double-blind, randomized, placebo-controlled, add-on
First manifestation schizophrenia
6 weeks400 mg/dayAmisulpride
(flexible dose)
Significant advantage of the COX-2 inhibitor

Adapted from [114].